Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated allogeneic mesenchymal stem cell infusions from different tissue sources in ARDS
IRCT20080901001165N44Phase 2Completed
- Sponsor
- Baqiyatallah University of Medical Sciences
- Start
- Mar 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of wharton's jelly mesenchymal stromal cells, bone marrow-derived mesenchymal stem cells and adipose derived mesenchymal stromal cells in acute respiratory distress syndrome (ARDS) (4 arms), sponsored by Baqiyatallah University of Medical Sciences. Primary endpoint: Number of patients with any unexpected severe adverse events including all-cause deaths. Started Mar 2020; status: completed.
02
Drugs
wharton's jelly mesenchymal stromal cellsbone marrow-derived mesenchymal stem cellsadipose derived mesenchymal stromal cells
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on IRCT20080901001165N44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20080901001165N44.